Difference between revisions of "Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[unchecked revision][unchecked revision]
Line 300: Line 300:
 
|
 
|
 
|-
 
|-
−
|Acute  Undifferentiated Leukemia||Disease|| ||JH
+
|    Acute  Undifferentiated Leukemia||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
+
|    Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease|| ||JH
+
|    Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease|| ||JH
+
|    Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease|| ||JH
+
|    Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types||Disease|| ||JH
+
|    ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease|| ||JH
+
|    ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease|| ||JH
 
|
 
|
 
|
 
|
Line 340: Line 340:
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1     ||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| ||YA
 
|
 
|
 
|
 
|
Line 460: Line 460:
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Plasma Cell Neoplasms||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Plasma Cell Myeloma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Plasma Cell Myeloma  Variants||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Plasmacytoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Monoclonal  Immunoglobulin Deposition Diseases||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|           Primary  Amyloidosis||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|           Light Chain  and Heavy Chain Deposition Disease||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|         POEMS Syndrome||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|         TEMPI Syndrome||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid  Tissue (MALT Lymphoma)||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Nodal Marginal Zone Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Paediatric Nodal  Marginal Zone Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Follicular Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Testicular Follicular  Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    In Situ Follicular  Neoplasia||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Duodenal-Type  Follicular Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Paediatric-Type Follicular Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Primary Cutaneous Follicle Centre Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Mantle Cell Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    In Situ Mantle Cell  Neoplasia||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
| || || ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||Greg Corboy (GC)
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||GC
 
|
 
|
 
|
 
|

Revision as of 17:41, 21 May 2020

Disease Page Type Author Associate Editor Author Content (Pending or Complete) Editor Reviewed (Date)
Myeloproliferative Neoplasms (MPN) Overview Fabiola Quintero-Rivera (FQR)
Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive Disease FQR
Chronic Neutrophilic Leukemia (CNL) Disease FQR
Polycythaemia Vera (PV) Disease FQR
Primary Myelofibrosis (PMF) Disease FQR
Essential Thrombocythaemia (ET) Disease FQR
Chronic Eosinophilic Leukemia, Not Otherwise Specified Disease FQR
Myeloproliferative Neoplasm (MPN), Unclassifiable Disease FQR
Mastocytosis Overview FQR
Cutaneous Mastocytosis Disease FQR
Systemic Mastocytosis Disease FQR
Mast Cell Sarcoma Disease FQR
Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2 Overview FQR
Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement Disease FQR
Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement Disease FQR
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Disease FQR
Myeloid/Lymphoid Neoplasms with PCM1-JAK2 Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Overview FQR
Chronic Myelomonocytic Leukemia (CMML) Disease FQR
Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative Disease FQR
Juvenile Myelomonocytic Leukemia (JMML) Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable Disease FQR
Myelodysplastic Syndromes (MDS) Overview FQR
Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia Disease FQR
Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) Disease FQR
Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia Disease FQR
Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia Disease FQR
Myelodysplastic Syndrome (MDS) with Excess Blasts Disease FQR
Myelodysplastic Syndrome (MDS) with Isolated del(5q) Disease FQR
Myelodysplastic Syndrome (MDS), Unclassifiable Disease FQR
Refractory Cytopenia of Childhood Disease FQR
Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms Overview Jennelle Hodge (JH)
Myeloid Neoplasms with Germline Predisposition Overview JH
Acute Myeloid Leukaemia with Germline CEBPA Mutation Disease JH
Myeloid Neoplasms with Germline DDX41 Mutation Disease JH
Myeloid Neoplasms with Germline RUNX1 Mutation Disease JH
Myeloid Neoplasms with Germline ANKRD26 Mutation Disease JH
Myeloid Neoplasms with Germline ETV6 Mutation Disease JH
Myeloid Neoplasms with Germline GATA2 Mutation Disease JH
Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities Overview JH
Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Disease JH
Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Disease JH
Acute Promyelocytic Leukemia (APL) with PML-RARA Disease JH
Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 Disease JH
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 Disease JH
Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM Disease JH
Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 Disease JH
Acute Myeloid Leukemia (AML) with BCR-ABL1 Disease JH
Acute Myeloid Leukemia (AML) with Mutated NPM1 Disease JH
Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA Disease JH
Acute Myeloid Leukemia (AML) with Mutated RUNX1 Disease JH
Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes Disease JH
Therapy-Related Myeloid Neoplasms Disease JH
Acute Myeloid Leukemia (AML), Not Otherwise Specified Overview JH
Acute Myeloid Leukemia (AML) with Minimal Differentiation Disease JH
Acute Myeloid Leukemia (AML) without Maturation Disease JH
Acute Myeloid Leukemia (AML) with Maturation Disease JH
Acute Myelomonocytic Leukemia Disease JH
Acute Monoblastic and Monocytic Leukemia Disease JH
Pure Erythroid Leukemia Disease JH
Acute Megakaryoblastic Leukemia (AMKL) Disease JH
Acute Basophilic Leukemia Disease JH
Acute Panmyelosis with Myelofibrosis Disease JH
Myeloid Sarcoma Disease JH
Myeloid Proliferations Associated with Down Syndrome Overview JH
Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome Disease JH
Myeloid Leukemia Associated with Down Syndrome Disease JH
Blastic Plasmacytoid Dendritic Cell Neoplasm Disease JH
Acute Leukemias of Ambiguous Lineage Overview JH
    Acute Undifferentiated Leukemia Disease JH
    Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 Disease JH
    Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged Disease JH
    Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified Disease JH
    Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified Disease JH
    ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types Disease JH
    ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS) Disease JH
Precursor Lymphoid Neoplasms Overview Yassmine Akkari (YA)
B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities Overview YA
    B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1     Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like Disease YA
    B-Lymphoblastic Leukemia/Lymphoma with iAMP21 Disease YA
    B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified Disease YA
T-Lymphoblastic Leukemia/Lymphoma Overview YA
Early T-Cell Precursor Lymphoblastic Leukemia Disease YA
NK-Lymphoblastic Leukemia/Lymphoma Disease YA
Mature B-Cell Neoplasms Overview Snehal Patel (SP)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Disease SP
       Monoclonal B-cell Lymphocytosis Disease SP
B-cell Prolymphocytic Leukemia Disease SP
Splenic Marginal Zone Lymphoma Disease SP
Hairy Cell Leukemia Disease SP
Splenic B-cell Lymphoma/Leukemia, Unclassifiable Overview SP
    Splenic Diffuse Red Pulp Small B-cell Lymphoma Disease SP
    Hairy Cell Leukemia Variant Disease SP
Lymphoplasmacytic Lymphoma Disease SP
   Waldenstrom Macroglobulinemia Disease SP
IgM Monoclonal Gammopathy of Undetermined Significance Disease SP
Heavy Chain Diseases Overview SP
    Mu Heavy Chain Disease Disease SP
   Gamma Heavy Chain Disease Disease SP
    Alpha Heavy Chain Disease Disease SP
Plasma Cell Neoplasms Overview SP
   Non-IgM Monoclonal Gammopathy of Undetermined Significance Disease SP
    Plasma Cell Myeloma Disease SP
    Plasma Cell Myeloma Variants Disease SP
    Plasmacytoma Disease SP
    Monoclonal Immunoglobulin Deposition Diseases Overview SP
           Primary Amyloidosis Disease SP
           Light Chain and Heavy Chain Deposition Disease Disease SP
Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome Overview SP
         POEMS Syndrome Disease SP
         TEMPI Syndrome Disease SP
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) Disease SP
Nodal Marginal Zone Lymphoma Disease SP
    Paediatric Nodal Marginal Zone Lymphoma Disease SP
Follicular Lymphoma Disease SP
    Testicular Follicular Lymphoma Disease SP
    In Situ Follicular Neoplasia Disease SP
    Duodenal-Type Follicular Lymphoma Disease SP
Paediatric-Type Follicular Lymphoma Disease SP
Large B-cell Lymphoma with IRF4 Rearrangement Disease SP
Primary Cutaneous Follicle Centre Lymphoma Disease SP
Mantle Cell Lymphoma Disease SP
    Leukemic Non-Nodal Mantle Cell Lymphoma Disease SP
    In Situ Mantle Cell Neoplasia Disease SP
Example Example Greg Corboy (GC)
Example Example GC
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Retrieved from "https://ccga.io/index.php?title=Volunteer_Assignments_and_Opportunities&oldid=7929"